Difference between revisions of "Quisinostat (JNJ-26481585)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://onlinelibrary.wiley.com" to "https://onlinelibrary.wiley.com") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 7: | Line 7: | ||
# Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. [https://onlinelibrary.wiley.com/doi/10.1111/bjd.14427/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26836950 PubMed] | # Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. [https://onlinelibrary.wiley.com/doi/10.1111/bjd.14427/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26836950 PubMed] | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
Revision as of 23:12, 13 June 2018
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Quisinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis.
Preliminary data
Cutaneous T-cell lymphoma
- Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. link to original article PubMed